Percutaneous Magnetically Levitated Extracorporeal Ventricular Assist Device

Core Technology Path

Full Magnetic Levitation

Rotor fully magnetically levitated throughout operation, no mechanical friction contact, extremely low hemolysis rate, safer

Percutaneous Cannulation

No thoracotomy required, procedure performed under transesophageal echocardiography, rapid circulatory support established within 15 minutes

Stable Hemodynamic Support

3-10L/min peak flow rate, meeting the full-spectrum treatment needs of cardiogenic shock

Core Advantages

The percutaneous magnetically levitated extracorporeal ventricular assist system integrates “full magnetic levitation” and percutaneous-access technologies, providing effective and comprehensive circulatory support for patients with acute heart failure or cardiogenic shock and for those undergoing high-risk PCI.

3-10 L/min

stable blood flow support capacity

2500-3000 rpm

core operating speed

4 weeks

safe support duration

15 min

rapid establishment of circulatory support

Information and data source: X-Flow Extracorporeal Ventricular Assist Device Product Technical Requirements

Development History

Full-process deployment from technology to clinic - Technology update every 1.5 years

2019

2019 EVAHEART Left Ventricular Assist Device was approved for market, becoming the first LVAD product approved for market in China, "marking the entry of China's severe heart failure treatment into the LVAD era."

2019

2022

2022 Global exclusive patent design Bioflow non-insertion vascular approved for market

2022

2023

2023 EVA-Pulsar Left Ventricular Assist Device approved for marketing

2023

2025

2025 New generation intelligent integrated controller approved for market launch. Equipped with intelligent integrated architecture with emergency backup battery, preventing accidental disconnection from the source.

2025

2026

2026 New Eva next generation Left Ventricular Assist Device under development and verification

2026